Aberdeen Group plc Purchases 88,853 Shares of Charles River Laboratories International, Inc. $CRL
Aberdeen Group plc significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by purchasing an additional 88,853 shares, bringing its total holdings to 97,001 shares valued at $19.35 million. Several other institutional investors, including Vanguard Group Inc., Ariel Investments LLC, Invesco Ltd., Bank of America Corp DE, and Dimensional Fund Advisors LP, also adjusted their positions in the medical research company. The article also provides a financial overview of Charles River Laboratories International, including its stock performance, recent earnings, guidance, and analyst ratings.
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
The New York Stock Exchange (NYSE) is providing a daily pre-market update directly from its trading floor, offering market insights before trading begins. The NYSE is also partnering with the AI conference HumanX in San Francisco, where Ashley Mastronardi will be speaking, and James Foster of Charles River Laboratories will join NYSE Live. Additionally, Olympic gold medalist Mikaela Shiffrin recently rang the Closing Bell, and Wichita State University commemorated its 100th year with an Opening Bell ceremony.
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
The New York Stock Exchange (NYSE) provides a daily pre-market update and is partnering with the HumanX AI conference in San Francisco. The update highlights equities rising due to a potential ceasefire with Iran and features Charles River Laboratories CEO James Foster speaking on NYSE Live. Additionally, Olympic gold medalist Mikaela Shiffrin rang the Closing Bell, and Wichita State University commemorated its 100th year.
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
The NYSE is partnering with the HumanX AI conference in San Francisco, where Ashley Mastronardi will speak to industry transformers. This update highlights a daily pre-market advisory from the NYSE trading floor, with Kristen Scholer delivering insights. It also mentions James Foster of Charles River Laboratories joining NYSE Live and Mikaela Shiffrin ringing the Closing Bell.
Charles River celebrates Jim Foster's 50-year career at NYSE
NYSE issues a pre-market update on April 6, 2026, featuring Kristen Scholer, and announcing a partnership with the AI conference HumanX. Charles River Laboratories CEO James Foster will discuss his 50-year career on NYSE Live, and Olympic gold medalist Mikaela Shiffrin recently rang the Closing Bell. The update also mentions Wichita State University's 100th-year commemoration.
Parsons wins 10-year Utah V2X infrastructure contract
Parsons Corporation has secured a 10-year contract with the Utah Department of Transportation to develop and maintain a statewide Vehicle-to-Everything (V2X) Maintenance and Management System. The company will implement its iNET software solution to create a cloud-based platform for monitoring and analyzing Utah's connected vehicle infrastructure. This new contract expands Parsons' transportation portfolio and establishes a significant customer relationship, further highlighting its role in modernizing infrastructure for automated mobility systems.
Biotech layoff pick back up as 14 companies cut 745 jobs in Q1
In the first quarter of 2026, 14 biotech companies announced layoffs, resulting in 745 job cuts. This number marks an increase from the previous quarter, which saw 476 workers lose their jobs. Companies such as Tessera, Vertex, and Takeda were among those implementing cuts.
CRL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Charles River Laboratories International Inc (CRL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. CRL's revenue is primarily driven by DSA (59.8%), with significant contributions from RMS and Manufacturing. The company reports a gross margin of 30.96%, an operating margin of 12.09%, and a net margin of -27.79%, alongside a market capitalization of $8.58B.
Lawson Kroeker Investment Management Inc. NE Sells 18,277 Shares of Charles River Laboratories International, Inc. $CRL
Lawson Kroeker Investment Management Inc. NE has decreased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.6%, selling 18,277 shares and now holding 31,638 shares valued at approximately $6.31 million. Despite this trimming, institutional ownership remains high at 98.91%, with several other major investors increasing their positions. Analysts maintain a "Moderate Buy" consensus rating for CRL, with an average target price of $206.15, following the company's strong Q4 EPS beat and a positive FY2026 guidance.
Charles River Laboratories International, Inc. (CRL) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Charles River Laboratories International, Inc. (CRL), including its current stock price, trading activity, key statistics, and historical data. The article details the company's business segments in drug discovery, non-clinical development, and safety testing, and includes performance overviews, earnings trends, and analyst insights. It also allows users to compare CRL with similar companies in the Diagnostics & Research industry.
Waters Corporation (WAT) stock price, news, quote and history
This article provides a detailed financial overview of Waters Corporation (WAT), covering its stock performance, key financial metrics, and company profile. It includes recent news, analyst insights, and comparisons with similar companies in the Diagnostics & Research industry, showing WAT's market position and operational scope.
Asure Software (NASDAQ: ASUR) details 2026 meeting, board pay and auditor
Asure Software (NASDAQ: ASUR) has detailed the agenda for its 2026 annual shareholder meeting, which will be held on May 12, 2026, in Austin, Texas. Shareholders will vote on the election of seven directors and the ratification of CBIZ CPAs PC as the independent auditor for 2026. The proxy statement also provides comprehensive information on board independence, committee structure, ESG programs, and executive and director compensation for 2025.
AAV Genome Sequencing Service Market Is Booming Rapidly with Strong Demand By 2033 | Thermo Fisher Scientific, Illumina, Danaher Corporation
Coherent Market Insights has published a new research study on the Global "AAV Genome Sequencing Service Market" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.
Artivion (AORT) details 2026 virtual meeting, director slate and Say on Pay
Artivion, Inc. (AORT) announced details for its virtual-only 2026 Annual Shareholder Meeting scheduled for May 12, 2026, at 9:00 a.m. ET. Shareholders as of March 16, 2026, will vote on the election of nine directors, the advisory "Say on Pay" resolution for executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for 2026. The Board of Directors recommends voting in favor of all proposals, highlighting that non-employee directors are independent and executive compensation aligns with company performance.
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Charles River Laboratories International Inc. (CRL) stock increased by 1.39% to $174.90 on Wednesday, marking its third consecutive day of gains. Despite this rise, the stock underperformed compared to the broader market, as the S&P 500 Index (SPX) gained 0.72% and the Dow Jones Industrial Average (DJIA) rose 0.48%.
CRL Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Charles River Laboratories International Inc (CRL) as of March 31, 2026. Intellectia.AI's proprietary analysis indicates a "Strong Buy" technical sentiment, though individual indicators show a mix of buy, sell, and neutral signals. The report details momentum indicators, support/resistance levels, and moving averages to offer a comprehensive technical outlook for CRL.
Lentiviral Vector Market Insights 2026–2035: Gene Therapy Growth and Manufacturing Trends
The lentiviral vector market is projected to reach $30.66 billion by 2030, growing at a CAGR of 12.8%. The market is fragmented, with Lonza Group AG leading in 2024 with a 2% share, and is driven by advanced vector engineering, high-efficiency transduction technologies, and scalable manufacturing platforms. Companies are focusing on high-titer production, enhanced safety, and regulatory compliance to meet the growing demand for gene and cell therapies.
[ARS] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing
This article announces an ARS SEC filing by Charles River Laboratories International, Inc. (CRL) on March 31, 2026. The filing indicates a low impact and neutral sentiment. The article also provides a brief overview of CRL's stock performance, latest news, and other SEC filings.
AI-led selloff in contract research firms may be misjudging disruption risk
Shares of contract research organizations (CROs) have dropped due to fears that AI advancements could allow drugmakers to conduct clinical trials in-house. However, industry experts and analysts argue that the selloff overestimates AI's ability to replace CROs' core services, such as global patient recruitment and trial execution, suggesting that AI is more likely to enhance efficiency rather than disrupt the sector. While investors are concerned, analysts believe there's no evidence of pharma companies reducing CRO spending due to AI, viewing it as a potential tailwind instead of a threat.
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL
Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (NYSE:CRL) by 8.4% in the fourth quarter of last year, selling 182,345 shares. Despite the reduction, CRL remains Allspring's 19th largest holding, valued at approximately $403.95 million. Other institutional investors have also adjusted their positions in CRL, while analysts maintain a "Moderate Buy" consensus rating for the company.
Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo
Charles River Laboratories International, Inc. (NYSE: CRL) is a cornerstone in the contract research organization (CRO) sector, providing essential research services for drug discovery and development. The company operates through three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. It holds a strong competitive position with a market capitalization of $9.70 billion, offering North American investors defensive growth within healthcare allocations.
Assenagon Asset Management S.A. Increases Stake in Charles River Laboratories International, Inc. $CRL
Assenagon Asset Management S.A. significantly increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 104.0% during the fourth quarter, now owning 65,879 shares valued at $13.14 million. This move is part of a broader trend of institutional investors adjusting their positions in the medical research company. Wall Street analysts currently rate CRL as a "Moderate Buy" with an average price target of $206.15, following recent adjustments in price objectives and ratings from various brokerages.
FibroBiologics (FBLG) files S-1 for $4.3M stock and warrant sale
FibroBiologics (FBLG) has filed an S-1 registration statement for a best efforts public offering to sell up to 1,136,363 shares of common stock or pre-funded warrants, each bundled with a warrant, plus additional placement agent warrants. The company expects to raise approximately $4.3 million in net proceeds, which will be used for working capital and general corporate purposes. This offering comes after a 1-for-20 reverse stock split, effective March 30, 2026, intended to help FibroBiologics regain compliance with Nasdaq's minimum bid-price requirement and attract broader investor interest.
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
Several healthcare and life science stocks, including RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen, saw declines in an afternoon session. This downturn was attributed to increased investor uncertainty stemming from the U.S.-Iran conflict and policy deadlines set by the Trump administration, leading to a broader market dip. The article suggests that such significant price drops could present investment opportunities for high-quality stocks.
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell by 3.62% to $159.16 on Friday, underperforming the broader market. This occurred during a session where the S&P 500 Index dropped 1.67% and the Dow Jones Industrial Average declined 1.73%. This marks the second consecutive day of losses for the company's stock.
FinancialContent - RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
Several stocks, including RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen, traded down following a sharp decline in major indices. This market reaction was attributed to escalating uncertainty surrounding the U.S.-Iran conflict, Trump administration policy deadlines, and a negative shift in consumer confidence. The article highlights that such big price drops can present buying opportunities for high-quality stocks and details Evolent Health's recent volatility and job report-related decline.
SG Americas Securities LLC Invests $36.26 Million in Charles River Laboratories International, Inc. $CRL
SG Americas Securities LLC has initiated a new position in Charles River Laboratories International, Inc. (NYSE:CRL), purchasing 181,778 shares valued at approximately $36.26 million in the fourth quarter. This investment comes as Charles River reported strong Q4 earnings, surpassing analyst estimates, and provided positive FY2026 guidance. The company holds a "Moderate Buy" rating from analysts with an average target price of $206.15.
Vanguard realigns holdings; Charles River (NYSE: CRL) shows 0% stake
Vanguard has reported a 0% beneficial ownership stake in Charles River Laboratories International, Inc. (NYSE: CRL) following an internal realignment that took effect on January 12, 2026. This change means certain Vanguard subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538, and Vanguard itself no longer claims beneficial ownership over those securities. The filing emphasizes that this is a change in reporting structure rather than an actual divestment, and future filings by the subsidiaries may reveal their individual holdings in Charles River.
Nordea Investment Management AB Grows Stock Position in Charles River Laboratories International, Inc. $CRL
Nordea Investment Management AB significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 43.6% in Q4, acquiring an additional 16,616 shares to reach a total of 54,694 shares valued at $10.99 million. This move is part of broader institutional interest, with other major investors like Vanguard Group and Ariel Investments also adjusting their positions in the medical research company. Charles River Laboratories reported strong quarterly earnings, beating analyst expectations, and has received a consensus "Moderate Buy" rating from analysts with an average price target of $206.15.
U.S. Sterility Testing Market Set to Boom Rapidly by 2033 | Thermo
The U.S. Sterility Testing Market is projected for substantial growth from 2026 to 2033, driven by increasing industry demand and technological advancements. A new report from Coherent Market Insights details market size, revenue trends, key growth factors, and a comprehensive competitive analysis, offering strategic insights for businesses. The study covers major market drivers, restraints, challenges, and opportunities, providing a foundation for informed, data-driven decisions.
Charles River extends gains as Evercore upgrades after Q1 beat
Charles River Laboratories saw its shares extend gains following an upgrade from Evercore ISI, driven by the company's strong first-quarter earnings that surpassed expectations. The upgrade to Outperform from In Line reflects Evercore's increased confidence in the company's future performance and valuation. The positive analyst sentiment contributed to the stock's upward momentum.
Charles River Labs stock faces technical shift to sideways amid mixed signals and 2026 guidance
Charles River Laboratories stock (ISIN: US1598641074) has shifted its technical trend from mildly bullish to sideways, trading at $153.05, down from its previous close. This change is influenced by mixed market signals, bearish MACD and Bollinger Bands, and a volatile 52-week range. Despite underperforming the S&P 500, the company's fiscal 2026 non-GAAP EPS guidance of $10.70–$11.20, projecting up to 9% growth through efficiency gains, offers a potential long-term value proposition for investors amid sector headwinds and R&D budget constraints.
Cancer drug researchers gain combined patient and genomics data
Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug development, particularly for solid tumors like lung, breast, and colorectal cancers, and aid in the discovery of new biomarker-based therapies.
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector?
Charles River Laboratories (CRL) has significantly underperformed the healthcare sector, with its stock dipping 31% from its 52-week high. Despite reporting better-than-expected Q4 results, shares have declined by 22.1% over the past three months and 20.8% YTD, lagging behind the State Street Health Care Select Sector SPDR ETF (XLV). Analysts, however, maintain a "Moderate Buy" rating with a mean price target suggesting a 28.1% premium.
Could Charles River (CRL) Using Locus Cell Tie-Up to Reframe Its Asia-Pacific Growth Strategy?
Charles River Laboratories (CRL) has signed an MoU with Locus Cell Co. to explore collaboration for advanced therapy support in the Asia-Pacific region, potentially strengthening CRL's position in cell and gene therapy services. This move could incrementally support Charles River's growth, especially in advanced therapies, while the company navigates industry changes and competitive pressures. The narrative projects significant revenue and earnings growth for Charles River by 2028, with a fair value of $215.73, suggesting a 40% upside.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) saw its stock price rise by 2.86% to $158.00 on Monday, outperforming the broader market. This gain occurred during a strong trading session where the S&P 500 Index increased by 1.15% and the Dow Jones Industrial Average rose by 1.38%. This marked the second consecutive day of gains for the company's stock.
Could Charles River (CRL) Using Locus Cell Tie-Up to Reframe Its Asia-Pacific Growth Strategy?
Charles River Laboratories recently signed an MoU with Locus Cell Co. to collaborate on advanced therapy development and testing in the Asia-Pacific region. This partnership aims to strengthen Charles River's position in the growing cell and gene therapy market, though its impact on near-term revenue growth and competition remains to be seen. The company's investment narrative projects significant revenue and earnings growth by 2028, but some analysts hold a more pessimistic view.
10,284 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Oliver Luxxe Assets LLC
Oliver Luxxe Assets LLC recently acquired 10,284 shares of Charles River Laboratories International, Inc. (NYSE:CRL) worth approximately $2.05 million in the fourth quarter, contributing to institutional investors now owning nearly 99% of the company. Analysts hold a "Moderate Buy" consensus rating with an average target price of $206.15. Charles River also surpassed quarterly earnings and revenue estimates, though it noted a negative net margin.
Charles River Laboratories Experiences Evaluation Revision Amid Mixed Market Signals
Charles River Laboratories International, Inc. has undergone an evaluation revision due to fluctuating market conditions. The stock, currently at $153.05, has shown significant volatility over the past year and has underperformed compared to major market indices, returning -13.50% against the S&P 500's 16.41% gain. Technical indicators present mixed signals, with some bullish tendencies on a monthly basis but generally bearish or unclear trends across different timeframes and indicators.
JPMorgan Chase & Co. Raises Stake in Charles River Laboratories International, Inc. $CRL
JPMorgan Chase & Co. has increased its stake in Charles River Laboratories International (NYSE:CRL) by 14.5% in the third quarter, bringing their total holdings to 317,179 shares valued at $49.6 million. This makes them a significant institutional investor in the medical research company. Other institutional investors also adjusted their positions, and Charles River Laboratories reported slightly better-than-expected earnings for the quarter but with a negative net margin.
Evotec SE stock faces ongoing pressure amid biotech sector volatility and negative earnings outlook
Evotec SE (ISIN: DE0005664809) stock is under pressure, trading around 4.30 EUR on Xetra, significantly down from its 52-week high, due to biotech sector volatility and negative earnings outlooks. The company, a German biotech services provider, faces profitability challenges and a tough funding environment, with analysts forecasting continued net losses into 2026. Despite its core business in drug discovery and strategic partnerships, investor caution is high, especially among DACH investors, due to pipeline risks and market sentiment.
Why is Charles River (CRL) down 6.8% since last earnings report?
This article explains that Charles River Laboratories (CRL) stock has fallen 6.8% since its last earnings report due to the company missing revenue estimates. Despite beating earnings per share expectations, the revenue miss and subsequent analyst downgrades contributed to the stock's decline. The article highlights key financial figures and analyst sentiment following the report.
Why is Charles River (CRL) down 6.8% since last earnings report?
The article discusses why Charles River Laboratories (CRL) stock has dropped 6.8% since its last earnings report. It likely analyzes financial performance, market reactions, or specific events that contributed to this decline, which the user would expect to be detailed within the full article content.
Confluence Investment Management LLC Has $21.07 Million Position in Charles River Laboratories International, Inc. $CRL
Confluence Investment Management LLC significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 10.1% in Q4, now holding 105,626 shares valued at $21.07 million. Institutional investors collectively own nearly 99% of the company's stock. Analysts provide a consensus "Moderate Buy" rating for CRL, with an average target price of $203.57, as the company slightly beat Q4 EPS estimates and provided FY2026 guidance.
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors
Charles River Laboratories International Inc. (CRL) stock fell by 2.58% to $153.05 on Thursday, underperforming the broader market as both the S&P 500 Index and Dow Jones Industrial Average also declined. This drop ended a two-day winning streak for the company's shares. The article notes that the stock's performance was in contrast to its competitors, though specific competitors are not named.
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day
Charles River Laboratories International Inc. (CRL) stock rose 2.21% to $157.11 on Wednesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for the company's shares.
Charles River Laboratories International, Inc. (NYSE:CRL) Sees Significant Increase in Short Interest
Short interest in Charles River Laboratories International (NYSE:CRL) surged by 19.8% in February, reaching 3,537,661 shares, which represents about 7.3% of its shares sold short. Despite slightly beating quarterly earnings and revenue estimates, the company's revenue was down year-over-year, and it provided full-year 2026 EPS guidance. Analysts currently have a "Moderate Buy" consensus rating for CRL with an average price target of $203.57.
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Charles River Laboratories International Inc. (CRL) stock rose 1.14% on Tuesday to $153.71, outperforming the broader market's gains as the S&P 500 and Dow Jones also increased. Despite the daily gain, CRL underperformed some competitors and remained 32.84% below its 52-week high reached back in January.
Aldeyra collects third CRL for reproxalap in dry eye disease
Aldeyra Therapeutics Inc. has received its third complete response letter (CRL) from the U.S. FDA for its dry eye disease candidate, reproxalap. The FDA cited a lack of substantial and consistent evidence of efficacy for the drug. This marks another setback for Aldeyra in its efforts to gain approval for reproxalap.
National Bank of Canada FI Grows Stock Position in Charles River Laboratories International, Inc. $CRL
National Bank of Canada FI significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 117.7% in the third quarter, bringing its total holdings to 946,769 shares valued at $148.13 million. This move is part of broader institutional investor activity in CRL, which sees 98.91% institutional ownership, a consensus "Moderate Buy" rating from analysts, and a consensus target price of $203.57. Despite beating recent quarterly earnings estimates, the company reported a negative net margin and P/E ratio, though it provided a positive EPS guidance for FY2026.
